172 related articles for article (PubMed ID: 26135517)
21. Comparing ranibizumab with bevacizumab.
Biswas P; Sengupta S; Choudhary R; Home S; Paul A; Sinha S
Ophthalmology; 2011 Mar; 118(3):600-600.e2. PubMed ID: 21376243
[No Abstract] [Full Text] [Related]
22. Antivascular endothelial growth factor bevacizumab for radiation optic neuropathy: secondary to plaque radiotherapy.
Finger PT; Chin KJ
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):789-98. PubMed ID: 21277107
[TBL] [Abstract][Full Text] [Related]
23. Intravitreal bevacizumab for perifoveal telangiectasia.
Jonas JB; Libondi T; von Baltz S; Beutelspacher S
Acta Ophthalmol; 2011 Nov; 89(7):e607-8. PubMed ID: 20946328
[No Abstract] [Full Text] [Related]
24. Visual improvement in central retinal vein occlusion (CRVO) following intravitreal injections of bevacizumab (Avastin(®) ).
Algvere PV; Von Wendt G; Gudmundsson J; Seregard S; Kvanta A
Acta Ophthalmol; 2010 Dec; 88(8):836-41. PubMed ID: 19900206
[TBL] [Abstract][Full Text] [Related]
25. Combined intravitreal bevacizumab and triamcinolone in exudative age-related macular degeneration.
Jonas JB; Libondi T; Golubkina L; Spandau UH; Schlichtenbrede F; Rensch F
Acta Ophthalmol; 2010 Sep; 88(6):630-4. PubMed ID: 19432871
[TBL] [Abstract][Full Text] [Related]
26. Management of radiation maculopathy.
Singh AD; Pabon S; Aronow ME
Ophthalmic Res; 2012; 48 Suppl 1():26-31. PubMed ID: 22907147
[TBL] [Abstract][Full Text] [Related]
27. Gemcitabine-Induced Retinopathy.
Jhaj G; Jhaj R; Shrier EM
Retina; 2017 Nov; 37(11):e130-e131. PubMed ID: 28961673
[No Abstract] [Full Text] [Related]
28. Diabetic macular edema.
Ghazi NG; Scruggs RT; Batchelet AR; Compton MW; Allam SS; Patrie J; Salti HI
Ophthalmology; 2012 Dec; 119(12):2643.e1. PubMed ID: 23207021
[No Abstract] [Full Text] [Related]
29. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
[TBL] [Abstract][Full Text] [Related]
30. Anti-VEGF Therapy Immediately after Plaque Radiation Therapy Prevents or Delays Radiation Maculopathy.
Powell BE; Finger PT
Ophthalmol Retina; 2020 May; 4(5):547-550. PubMed ID: 32192938
[No Abstract] [Full Text] [Related]
31. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
Ding X; Li J; Hu X; Yu S; Pan J; Tang S
Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
[TBL] [Abstract][Full Text] [Related]
32. Effect of combination therapy with bevacizumab and dexamethasone intravitreal implant in patients with retinal vein occlusion.
Singer MA; Bell DJ; Woods P; Pollard J; Boord T; Herro A; Porbandarwalla S
Retina; 2012 Jul; 32(7):1289-94. PubMed ID: 22466480
[TBL] [Abstract][Full Text] [Related]
33. Combined photodynamic therapy with intravitreal bevacizumab injections for polypoidal choroidal vasculopathy: long-term visual outcome.
Kang HM; Koh HJ; Lee CS; Lee SC
Am J Ophthalmol; 2014 Mar; 157(3):598-606.e1. PubMed ID: 24269378
[TBL] [Abstract][Full Text] [Related]
34. Radiation optic neuropathy after proton beam therapy for optic nerve sheath meningioma.
Siddiqui JD; Loeffler JS; Murphy MA
J Neuroophthalmol; 2013 Jun; 33(2):165-8. PubMed ID: 23429064
[TBL] [Abstract][Full Text] [Related]
35. Systemic beta-blockers may reduce the need for repeated intravitreal injections in patients with wet age-related macular degeneration treated by bevacizumab.
Montero JA; Ruiz-Moreno JM; Sanchis-Merino E; Perez-Martin S
Retina; 2013 Mar; 33(3):508-12. PubMed ID: 23099497
[TBL] [Abstract][Full Text] [Related]
36. Expression of vascular endothelial growth factor and intravitreal anti-VEGF therapy with bevacizumab in vasoproliferative retinal tumors.
Saito W; Kase S; Fujiya A; Dong Z; Noda K; Ishida S
Retina; 2013 Oct; 33(9):1959-67. PubMed ID: 23652580
[TBL] [Abstract][Full Text] [Related]
37. Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials.
Rosenfeld PJ; Shapiro H; Tuomi L; Webster M; Elledge J; Blodi B;
Ophthalmology; 2011 Mar; 118(3):523-30. PubMed ID: 20920825
[TBL] [Abstract][Full Text] [Related]
38. Intravitreal bevacizumab in myopic neovascular membranes: 24-month results.
Ruiz-Moreno JM; López-Gálvez MI; Montero Moreno JA; Pastor Jimeno JC
Ophthalmology; 2013 Jul; 120(7):1510-1.e1. PubMed ID: 23823510
[No Abstract] [Full Text] [Related]
39. One-year outcomes of less frequent bevacizumab in age-related macular degeneration.
Sonmez K; Sonmez PA; Ozkan SS; Atmaca LS
Retina; 2011 Apr; 31(4):645-53. PubMed ID: 21358363
[TBL] [Abstract][Full Text] [Related]
40. Outcomes of anti-vascular endothelial growth factor therapy in the management of choroidal neovascularization associated with choroidal osteoma.
Khan MA; DeCroos FC; Storey PP; Shields JA; Garg SJ; Shields CL
Retina; 2014 Sep; 34(9):1750-6. PubMed ID: 24936941
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
